14 авг. 2020 г. · The artificial intelligence-powered drug designer Atomwise has raised $123 million in venture capital funding, to both scale up its platform and its ...

19 нояб. 2024 г. · Atomwise has raised a total funding of $174M over 7 rounds from 29 investors. Investors include DFJ, DCVC and 27 others.

11 авг. 2020 г. · Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an ...

03/07/2024, Series C ; Price per Share. $xx.xx. Shares Outstanding. 89,416,880. Liquidation Pref Order. 1. Liquidation Pref As Multiplier. 2.0x. Conversion Ratio.

17 авг. 2022 г. · Sanofi will pay Atomwise $20 million upfront to identify, synthesize, and advance lead compounds for up to five targets which will be exclusive to Sanofi.

Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for disease targets. The company's technology ...

2 окт. 2023 г. · Atomwise, one of the first startups to start pitching an AI revolution in drug discovery just over a decade ago is now taking a page.

12 авг. 2020 г. · Drug discovery startup Atomwise recently raised $123 million bringing the total amount of capital the company has raised to date to almost ...

Atomwise is the developer of first deep learning technology designed for structure-based small molecule drug discovery.

2 апр. 2024 г. · Atomwise is a TechBio company leveraging AI/ML to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for ...